NCT04091217View on ClinicalTrials.gov

Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 25, 2019

Primary Completion Date

August 31, 2022

Study Completion Date

September 1, 2023

Conditions

Melanoma

Interventions

DRUG

Atezolizumab

Atezolizumab 1200 mg will be administered intravenously every 3 weeks.

DRUG

Bevacizumab

Bevacizumab 7.5 mg/kg will be administered intravenously every 3 weeks.

Trial Locations (3)

100142

Beijing Cancer Center; Renal Cancer And Melanoma Department., Beijing

310022

Zhejiang Cancer Hospital, Zhejiang

350014

Fujian Provincial Cancer Hospital, Fuzhou

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT04091217 - Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma | Biotech Hunter | Biotech Hunter